• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ARYC
Share

Arrayit Corporation Stocks

$ 0Last Updated 28.07.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 7935

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Arrayit Corporation, headquartered in Sunnyvale, California, operates as a global life sciences technology firm. The company is dedicated to developing, manufacturing, and commercializing advanced tools and integrated systems for comprehensive analysis of genetic variations, biological functions, and diagnostic applications worldwide. Its core activities encompass the creation and maintenance of microarray instruments and components, providing bespoke microarray printing and analysis services for research, and pioneering diagnostic microarrays designed for the early identification of treatable health conditions. Arrayit's innovative microarray printing technology facilitates the production of diverse microarray types—including DNA, protein, antibody, lipid, and carbohydrate—suitable for a wide array of research and diagnostic uses such as gene expression studies, genotyping, and protein profiling. The company's product portfolio extends to automated microarray manufacturing instruments like the NanoPrint, various SpotBot models (Titan, Extreme, Protein), and Personal microarrayers. It also supplies a range of scanning devices, including SpotLight CCD and SpotWare colorimetric scanners, InnoScan laser scanners, alongside hybridization stations (TrayMix, ArrayMix), centrifuges, air jets, vacuum equipment, general laboratory tools, and bioinformatics computing solutions. Additionally, Arrayit manufactures essential consumables such as glass substrates and slides, reagents, solutions, kits, and clean room provisions. A notable offering is its variation identification platform technology, which enables diagnostic tests by accommodating approximately 100,000 patient samples on a single microarray. The company further diversifies its operations through the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation serves a broad spectrum of clients, including genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology firms.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 16:01

Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026